Physician profile
Anne Feaster
NPI 1932259652
$15,197.01
in general payments reported to CMS, 2019-2025
68 companies · $1,836 in 2025
The $1,836 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,495 · 2022: $4,217 · 2023: $4,277 · 2024: $3,372 · 2025: $1,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,356 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,356.45 |
| Education | $129.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,384.13 | 2021-2025 | Erleada, Darzalex, Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $1,078.58 | 2021-2025 | Reblozyl, Opdualag, Opdivo |
| Novartis Pharmaceuticals Corporation | $1,004.20 | 2021-2025 | |
| Daiichi Sankyo INC. | $728.01 | 2021-2025 | Enhertu, Injectafer |
| Incyte Corporation | $626.69 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $593.67 | 2021-2025 | Enhertu, Calquence, Imfinzi |
| Merck Sharp & Dohme LLC | $584.34 | 2021-2025 | Keytruda, Lynparza |
| Astellas Pharma US INC | $497.89 | 2021-2025 | Xtandi, Vyloy, Xospata |
| Amgen INC. | $443.53 | 2021-2024 | Blincyto, Kyprolis, Nplate |
| Pfizer INC. | $420.16 | 2021-2025 | |
| Eisai INC. | $405.14 | 2022-2025 | |
| Gilead Sciences, INC. | $404.52 | 2021-2025 | Trodelvy |
| Abbvie INC. | $392.98 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $357.42 | 2021-2023 | Imbruvica, Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $354.82 | 2021-2024 | Ninlaro, Alunbrig, Fruzaqla |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $335.47 | 2021-2025 | Epkinly, Tivdak |
| Karyopharm Therapeutics INC. | $317.53 | 2023-2025 | Xpovio |
| Genentech USA, INC. | $311.80 | 2021-2024 | Polivy, Venclexta, Lunsumio |
| Seagen INC. | $302.97 | 2021-2023 | Padcev, Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $284.05 | 2021-2025 | |
| Celgene Corporation | $282.23 | 2022-2025 | Reblozyl, Pomalyst |
| Glaxosmithkline, LLC. | $275.68 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Lilly USA, LLC | $255.82 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Emd Serono, INC. | $221.77 | 2021-2024 | Bavencio |
| Regeneron Healthcare Solutions, INC. | $206.62 | 2022-2025 | Libtayo |
| Array Biopharma INC | $196.09 | 2021-2024 | Braftovi, Mektovi, Lorbrena |
| Genzyme Corporation | $192.39 | 2021-2024 | |
| Puma Biotechnology, INC. | $172.78 | 2021-2025 | Nerlynx |
| Morphosys, US INC. | $171.17 | 2021-2024 | Monjuvi |
| Stemline Therapeutics INC. | $152.20 | 2023-2025 | Orserdu |
| Pharmacosmos Therapeutics INC. | $140.37 | 2021-2025 | Monoferric |
| Myovant Sciences INC. | $137.30 | 2021-2022 | |
| Blueprint Medicines Corporation | $128.71 | 2022-2023 | Ayvakit |
| Kite Pharma, INC. | $127.46 | 2022-2025 | Yescarta |
| Acrotech Biopharma INC. | $121.42 | 2021-2024 | Beleodaq |
| Tersera Therapeutics LLC | $103.85 | 2022-2024 | Zoladex |
| Exelixis INC. | $98.18 | 2023-2025 | Cabometyx |
| Rigel Pharmaceuticals, INC. | $93.79 | 2021-2024 | Tavalisse, Rezlidhia |
| Beone Medicines USA, INC. | $85.42 | 2025 | Brukinsa |
| Sobi, INC | $82.94 | 2022-2025 | |
| Mirati Therapeutics, INC. | $74.54 | 2023-2024 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.00 | 2021-2023 | Gilotrif |
| Apellis Pharmaceuticals, INC. | $69.43 | 2023-2024 | Empaveli |
| Mylan Institutional INC. | $68.16 | 2022-2023 | Ogivri, Fulphila |
| Ipsen Biopharmaceuticals, INC | $66.73 | 2024-2025 | Onivyde, Somatuline Depot |
| G1 Therapeutics, INC. | $66.46 | 2023 | Cosela |
| Myriad Genetic Laboratories, INC. | $65.43 | 2022-2024 | Myrisk |
| Taiho Oncology, INC. | $59.09 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $58.02 | 2021-2023 | Xarelto |
| Sumitomo Pharma America, INC. | $49.33 | 2023 | Orgovyx |
| Jazz Pharmaceuticals INC. | $47.09 | 2021-2024 | |
| Pharmaessentia USA Corporation | $41.25 | 2022-2023 | Besremi |
| Aveo Pharmaceuticals, INC. | $38.46 | 2024 | |
| Foundation Medicine, INC. | $38.01 | 2023 | Foundationone Cdx |
| Recordati_rare_diseases_inc. | $33.59 | 2024-2025 | Sylvant |
| Organon LLC | $32.22 | 2023 | Ontruzant |
| Immunogen, INC. | $28.80 | 2023 | Elahere |
| Adc Therapeutics America, INC. | $25.49 | 2021-2024 | |
| Kyowa Kirin, INC. | $24.54 | 2023 | Poteligeo |
| Iovance Biotherapeutics, INC. | $23.93 | 2025 | Amtagvi |
| Csl Behring | $21.31 | 2024 | Hizentra |
| Alexion Pharmaceuticals, INC. | $19.61 | 2024 | Ultomiris |
| Beigene USA, INC. | $19.29 | 2024 | Brukinsa |
| Heron Therapeutics, INC. | $18.96 | 2022 | |
| Servier Pharmaceuticals LLC | $15.71 | 2024 | |
| Clovis Oncology, INC. | $15.49 | 2021 | |
| Secura Bio, INC. | $15.02 | 2024 | Copiktra |
| Cumberland Pharmaceuticals, INC. | $13.96 | 2024 | Sancuso |
Drugs and devices associated with these payments
Reblozyl $492Enhertu $418Lenvima $374Erleada $358Xpovio $318Keytruda $286Epkinly $272Monjuvi $260Trodelvy $252Jakafi $247Xtandi $244Imbruvica $213Darzalex $207Kisqali $195Libtayo $192Lynparza $172Bavencio $171Venclexta $163Stivarga $153Orserdu $152Braftovi $135Mektovi $134Fabhalta $130Lorbrena $126Verzenio $125Opdualag $117Tivdak $115Elahere $114Pemazyre $113Brukinsa $105Ayvakit $99.71Cabometyx $98.18Jemperli $97.62Zejula $97.62Calquence $97.37Ninlaro $91.68Nubeqa $81.87Ibrance $79.86Xalkori $77.87Retevmo $75.37Jaypirca $75.37Zoladex $74.63Krazati $74.54Padcev $74.42Nerlynx $73.68Polivy $72.76Promacta $72.32Imfinzi $71.86Piqray $70.26Empaveli $69.43Somatuline Depot $66.73Onivyde $66.73Mekinist $66.55Cosela $66.46Comirnaty $66.38Injectafer $66.14Vonjo $65.56Enjaymo $65.08Vyloy $64.41Ojjaara $57.74Opdivo $57.67Beleodaq $57.33Tukysa $56.04Monoferric $56.00Blincyto $52.14Kyprolis $52.14Alunbrig $52.09Lupron Depot $50.13Orgovyx $49.33Tecvayli $47.94Xofigo $47.56Gilotrif $44.44Talvey $43.90Yescarta $43.66Augtyro $43.24Carvykti $42.18Besponsa $41.28Bosulif $41.28Xgeva $40.97Nplate $40.97Vectibix $40.97Blenrep $40.83Myrisk $40.04Lutathera $38.80Fotivda $38.46Scemblix $37.54Paxlovid $36.89Sarclisa $35.48Pluvicto $34.69Sylvant $33.59Fruzaqla $32.66Vitrakvi $32.42Ontruzant $32.22Zepzelca $28.97Xarelto $26.05Jevtana $25.96Poteligeo $24.54Amtagvi $23.93Fulphila $23.66Ogivri $23.66
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Feaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.